The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Partnership agreement with Software Provider

14 Nov 2022 07:00

RNS Number : 2097G
Omega Diagnostics Group PLC
14 November 2022
 

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Partnership agreement with Nutrigenomics Software Provider

Creating detailed lifestyle and dietary guidance reports from genetic data

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has signed heads of terms with regards to a partnership agreement (the "Agreement") with a leading nutrigenomics software provider to develop and commercialise a bespoke DNA report for Omega.

 

The report will be a unique and proprietary software tool which will expand the Company's product portfolio in line with its stated strategy to broaden its menu of tests. By understanding the relationship between nutrients, diet, and gene expression, nutrigenomics allows healthcare professionals to understand genetic strengths and weaknesses, making specific recommendations that help achieve better health outcomes for patients.

 

The parties will collaborate with a view to improving the awareness and understanding in the market of nutrigenomic testing, including the publication of educational materials and scientific studies. The report, which is intended to be utilised by healthcare professionals and their patients, will be designed to meet Omega's specific requirements while incorporating the current data and structure of the software provider's existing reports.

 

This Agreement follows on from the microbiome testing partnership which was announced on 26 October 2022 and, once completed, will conclude the Company's initial product range expansion as previously set out in the Company's strategic plan.

 

Jag Grewal, CEO of Omega Diagnostics said: "We are pleased to have signed this second strategic partnership, this time with a leading nutrigenomics software provider, which will give the Company a broader and complementary range of tests to help manage gut health and improve patient outcomes for those living with chronic diseases. Our focus remains on commercial and service development within the sector, as we seek to grow revenues and further consolidate our established market leading position, thus enabling the Board's vision of delivering personalised nutrition for better health."

 

Contacts: 

 

Omega Diagnostics Group PLC

www.omegadx.com

Jag Grewal, Chief Executive Officer 

via Walbrook PR

Chris Lea, Chief Financial Officer

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)

Alice Lane/Charlotte Sutcliffe (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus / Sam Allen / Lianne Applegarth

Mob: 07980 541 893 / 07502 558 258 / 07584 391 303

 

About Omega Diagnostics Group PLC

Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.

www.omegadx.com

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFLDLRLLLIF
Date   Source Headline
2nd Mar 20217:00 amRNSContract with Screen4
24th Feb 20217:00 amRNSUK-RTC statement on AbC-19TM rapid antibody test
19th Feb 20211:45 pmRNSDirector/PDMR Shareholding
18th Feb 202110:00 amRNSDirector/PDMR Shareholding
16th Feb 20217:00 amRNSAbC-19TM rapid antibody test performance data
15th Feb 20217:00 amRNSDirector/PDMR Shareholding
11th Feb 20219:00 amRNSPrice Monitoring Extension
11th Feb 20217:01 amRNSUK Government contract and trading update
11th Feb 20217:00 amRNSDirectorate Change
8th Feb 20219:05 amRNSSecond Price Monitoring Extn
8th Feb 20219:00 amRNSPrice Monitoring Extension
8th Feb 20217:00 amRNSStatement re Media Comment
2nd Feb 20218:45 amRNSExercise of Options and Total Voting Rights
28th Jan 20211:15 pmRNSExercise of Options and Total Voting Rights
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:35 pmRNSPrice Monitoring Extension
26th Jan 20217:02 amRNSLab-based COVID-19 antibody test service launch
26th Jan 20217:01 amRNSUpdate re AbC-19 Rapid Test
25th Jan 202111:06 amRNSSecond Price Monitoring Extn
25th Jan 202111:00 amRNSPrice Monitoring Extension
22nd Jan 202110:15 amRNSExercise of Options and Total Voting Rights
22nd Jan 20219:05 amRNSSecond Price Monitoring Extn
22nd Jan 20219:00 amRNSPrice Monitoring Extension
11th Jan 202111:00 amRNSExercise of Options and Total Voting Rights
29th Dec 20207:01 amRNSUpdate re AbC-19 Rapid Test
29th Dec 20207:00 amRNSAbC-19TM Rapid Test Update
24th Dec 202012:41 pmRNSSecond Price Monitoring Extn
24th Dec 202012:35 pmRNSPrice Monitoring Extension
24th Dec 202012:00 pmRNSMologic CE Mark Rapid Antigen Test
24th Dec 202011:05 amRNSSecond Price Monitoring Extn
24th Dec 202011:00 amRNSPrice Monitoring Extension
11th Dec 20202:05 pmRNSSecond Price Monitoring Extn
11th Dec 20202:00 pmRNSPrice Monitoring Extension
11th Dec 20209:45 amRNSExercise of Options and Total Voting Rights
7th Dec 20208:00 amRNSExercise of Options and Total Voting Rights
2nd Dec 20209:00 amRNSDirector/PDMR Shareholding
30th Nov 20202:30 pmRNSExercise of Options and Total Voting Rights
30th Nov 20207:00 amRNSInterim Results
25th Nov 20202:06 pmRNSSecond Price Monitoring Extn
25th Nov 20202:01 pmRNSPrice Monitoring Extension
23rd Nov 20209:45 amRNSExercise of Options and Total Voting Rights
17th Nov 20207:45 amRNSUK-RTC Update
16th Nov 20207:16 amRNSHolding(s) in Company
16th Nov 20207:15 amRNSHolding(s) in Company
13th Nov 20202:05 pmRNSSecond Price Monitoring Extn
13th Nov 20202:00 pmRNSPrice Monitoring Extension
13th Nov 20209:30 amRNSExercise of Options and Total Voting Rights
12th Nov 20203:42 pmRNSUK-RTC Statement
12th Nov 202011:05 amRNSSecond Price Monitoring Extn
12th Nov 202011:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.